-
Posted by
Two Blokes Jun 25 -
Filed in
Stock
-
2 views
LIKMEZ\u2122 (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, June 25, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2025 (“FYE 2025”), and provided an update on fiscal 2026. All figures are stated in Canadian dollars unless otherwise stated.
